Avantax Advisory Services Inc. Purchases 7,282 Shares of Boston Scientific Co. (NYSE:BSX)

Avantax Advisory Services Inc. increased its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 25.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,416 shares of the medical equipment provider's stock after acquiring an additional 7,282 shares during the period. Avantax Advisory Services Inc.'s holdings in Boston Scientific were worth $3,253,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in BSX. State Street Corp boosted its stake in Boston Scientific by 2.3% during the 3rd quarter. State Street Corp now owns 62,846,328 shares of the medical equipment provider's stock valued at $5,266,522,000 after purchasing an additional 1,389,172 shares in the last quarter. Wellington Management Group LLP boosted its stake in Boston Scientific by 2.2% during the third quarter. Wellington Management Group LLP now owns 32,820,828 shares of the medical equipment provider's stock valued at $2,750,385,000 after buying an additional 718,515 shares in the last quarter. Geode Capital Management LLC boosted its stake in Boston Scientific by 1.7% during the third quarter. Geode Capital Management LLC now owns 29,584,841 shares of the medical equipment provider's stock valued at $2,469,607,000 after buying an additional 480,729 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Boston Scientific by 5.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 8,475,031 shares of the medical equipment provider's stock worth $756,990,000 after acquiring an additional 456,654 shares during the period. Finally, Fisher Asset Management LLC lifted its holdings in Boston Scientific by 21.6% in the 4th quarter. Fisher Asset Management LLC now owns 5,800,912 shares of the medical equipment provider's stock valued at $518,138,000 after acquiring an additional 1,028,977 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Remove Ads

Boston Scientific Stock Up 0.3 %

Shares of BSX traded up $0.27 during midday trading on Tuesday, reaching $99.17. 5,370,015 shares of the stock were exchanged, compared to its average volume of 5,741,979. The company has a market cap of $146.36 billion, a price-to-earnings ratio of 79.34, a P/E/G ratio of 2.79 and a beta of 0.77. The firm has a 50 day simple moving average of $101.35 and a 200-day simple moving average of $92.09. Boston Scientific Co. has a 12-month low of $66.80 and a 12-month high of $107.17. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Research analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current year.

Insider Activity at Boston Scientific

In other Boston Scientific news, CFO Daniel J. Brennan sold 67,333 shares of the firm's stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $105.24, for a total transaction of $7,086,124.92. Following the transaction, the chief financial officer now directly owns 225,808 shares in the company, valued at $23,764,033.92. This trade represents a 22.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the sale, the executive vice president now owns 5,502 shares of the company's stock, valued at approximately $560,103.60. This trade represents a 75.88 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 137,302 shares of company stock valued at $14,319,269. Insiders own 0.50% of the company's stock.

Analysts Set New Price Targets

BSX has been the topic of several recent research reports. JPMorgan Chase & Co. lifted their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an "overweight" rating in a research note on Monday, December 16th. Royal Bank of Canada raised their price objective on Boston Scientific from $105.00 to $116.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. Needham & Company LLC restated a "hold" rating on shares of Boston Scientific in a report on Monday, March 3rd. Raymond James upped their target price on Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a report on Thursday, February 6th. Finally, Truist Financial lifted their price target on Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a research note on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of "Moderate Buy" and an average price target of $108.91.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.